Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
Clinical trial NCT00526045 · COMPLETED
Trial details
- NCT number
- NCT00526045
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-07-01
- Primary completion
- 2012-04-01
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.